Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling
Susan M. Lin, … , Jillian F. Evans, Vera P. Krymskaya
Susan M. Lin, … , Jillian F. Evans, Vera P. Krymskaya
Published December 21, 2023
Citation Information: J Clin Invest. 2024;134(4):e172116. https://doi.org/10.1172/JCI172116.
View: Text | PDF
Research Article Cell biology Vascular biology

Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling

  • Text
  • PDF
Abstract

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease caused by tuberous sclerosis complex 1/2 (TSC1/2) gene mutations in pulmonary mesenchymal cells, resulting in activation of the mechanistic target of rapamycin complex 1 (mTORC1). A subset of patients with LAM develop pulmonary vascular remodeling and pulmonary hypertension. Little, however, is known regarding how LAM cells communicate with endothelial cells (ECs) to trigger vascular remodeling. In end-stage LAM lung explants, we identified EC dysfunction characterized by increased EC proliferation and migration, defective angiogenesis, and dysmorphic endothelial tube network formation. To model LAM disease, we used an mTORC1 gain-of-function mouse model with a Tsc2 KO (Tsc2KO) specific to lung mesenchyme (Tbx4LME-Cre Tsc2fl/fl), similar to the mesenchyme-specific genetic alterations seen in human disease. As early as 8 weeks of age, ECs from mice exhibited marked transcriptomic changes despite an absence of morphological changes to the distal lung microvasculature. In contrast, 1-year-old Tbx4LME-Cre Tsc2fl/fl mice spontaneously developed pulmonary vascular remodeling with increased medial thickness. Single-cell RNA-Seq of 1-year-old mouse lung cells identified paracrine ligands originating from Tsc2KO mesenchyme, which can signal through receptors in arterial ECs. These ECs had transcriptionally altered genes including those in pathways associated with blood vessel remodeling. The proposed pathophysiologic mesenchymal ligand–EC receptor crosstalk highlights the importance of an altered mesenchymal cell/EC axis in LAM and other hyperactive mTORC1–driven diseases. Since ECs in patients with LAM and in Tbx4LME-Cre Tsc2fl/fl mice did not harbor TSC2 mutations, our study demonstrates that constitutively active mTORC1 lung mesenchymal cells orchestrated dysfunctional EC responses that contributed to pulmonary vascular remodeling.

Authors

Susan M. Lin, Ryan Rue, Alexander R. Mukhitov, Akansha Goel, Maria C. Basil, Kseniya Obraztsova, Apoorva Babu, Slaven Crnkovic, Owen A. Ledwell, Laura T. Ferguson, Joseph D. Planer, Ana N. Nottingham, Kanth Swaroop Vanka, Carly J. Smith, Edward Cantu III, Grazyna Kwapiszewska, Edward E. Morrisey, Jillian F. Evans, Vera P. Krymskaya

×

Figure 4

Inhibition of WNT suppresses EC proliferation, migration, and angiogenesis.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of WNT suppresses EC proliferation, migration, and angiogenes...
(A) Control ECs (n = 6) and LAM ECs cells (n = 3) were treated with 1 μM of the WNT inhibitor C82 followed by a proliferation assay as described in Methods. (B) Representative images of migration of ECs from LAM lung treated with 1 μM C82 or diluent (control). Original magnification, ×10. (C) Statistical analysis of LAM EC migration calculated as the number of cells/field in control (n = 5) versus 1 μM C82-treated LAM ECs (n = 5). (D) Representative images from angiogenesis assay of control ECs and LAM ECs treated with diluent or 1 μM C82. (E) Analysis of total tube length of control ECs compared with LAM ECs was performed using the Angiogenesis Analyzer plugin on ImageJ followed by statistical analysis by 2-tailed t test, with the control condition taken as 100%. (F) Effect of 10 nM rapamycin and 1 μM C82 on EC-fibroblast cocultures. (G) EC-fibroblast cocultures of control human ECs with control human lung fibroblasts were treated with diluent (control) and stimulated with the pan-WNT pathway activator CHIR99021 (3 μM) or WNT2 (100 ng/mL). n = 3 per treatment group. Scale bars: 250 μm. (H) Statistical analysis of ECs per field (with a minimum of 4 images per well) in cocultures treated with WNT2 was performed using a 2-tailed t test, and data are presented as the mean ± SEM. ***P < 0.001 and ****P < 0.0001 (A, C, E, and H). Nonparametric t test (Mann-Whitney) (A and E).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts